M. Archambaud
Impact in
- Endocrinology top 1%
- Escherichia coli research studies
- Enterobacteriaceae and Cronobacter Research
- Molecular Medicine top 1%
- Antibiotic Resistance in Bacteria
Papers in
-
- Antibiotic Resistance in Bacteria 9
-
- Antibiotic Use and Resistance 3
M. Archambaud
26 papers receiving 706 citations
Peers
Comparison fields: 5 of 69
- Endocrinology 380
- Molecular Medicine 307
- Applied Microbiology and Biotechnology 84
- Infectious Diseases 197
- Pharmacology 132
Countries citing papers authored by M. Archambaud
This map shows the geographic impact of M. Archambaud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Archambaud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Archambaud more than expected).
Fields of papers citing papers by M. Archambaud
This network shows the impact of papers produced by M. Archambaud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Archambaud. The network helps show where M. Archambaud may publish in the future.
Co-authorship network
The 25 scholars most cited alongside M. Archambaud, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2013 | 0 | |
| 2 | 2012 | 15 | |
| 3 | 2010 | 44 | |
| 4 | 2007 | 5 | |
| 5 | 2007 | 2 | |
| 6 | 2006 | 27 | |
| 7 | 2006 | 39 | |
| 8 | 2005 | 70 | |
| 9 | 2004 | 33 | |
| 10 | 2002 | 2 | |
| 11 | [Continuous versus intermittent cefepime infusion in critical care. Preliminary results]. | 1999 | 15 |
| 12 | [Bartonella endocarditis on native valves. Apropos of 2 cases]. | 1998 | 1 |
| 13 | [Severe methicillin-resistant Staphylococcus aureus infections. Emergence of resistance to fusidic acid or fosfomycin during treatment with continuous infusion of vancomycin]. | 1997 | 7 |
| 14 | 1991 | 32 | |
| 15 | 1988 | 27 | |
| 16 | 1988 | 22 | |
| 17 | 1988 | 46 | |
| 18 | [In vitro study of the effects of oxolinic acid at sub-inhibitory concentrations on the activity of hemagglutinins and adhesion to uroepithelial cells by Escherichia coli isolated from urine]. | 1987 | 2 |
| 19 | 1987 | 30 | |
| 20 | [Haemagglutinins and adhesins of Escherichia coli strains isolated from urine: inhibitory effect of sub-inhibitory concentrations of tetracycline, doxycycline and minocycline. Preliminary results ]. | 1982 | 4 |
About M. Archambaud
M. Archambaud is a scholar working on Molecular Medicine, Applied Microbiology and Biotechnology, Endocrinology, Virology and Infectious Diseases, having authored 27 papers that have together received 740 indexed citations. Recurring topics across this work include Antibiotic Resistance in Bacteria (9 papers), Antibiotics Pharmacokinetics and Efficacy (5 papers), Antimicrobial Resistance in Staphylococcus (4 papers), Urinary Tract Infections Management (4 papers), Escherichia coli research studies (4 papers), Antibiotic Use and Resistance (3 papers), Infective Endocarditis Diagnosis and Management (3 papers) and Enterobacteriaceae and Cronobacter Research (2 papers). The work is most often cited by research in Endocrinology (380 citations), Molecular Medicine (307 citations), Applied Microbiology and Biotechnology (84 citations), Infectious Diseases (197 citations) and Pharmacology (132 citations). M. Archambaud has collaborated with scholars based in France and United States. Frequent co-authors include A Labigne, C. Le Bouguénec, G. Chabanon, A Labigne-Roussel, P Courcoux, N. Marty, É. Bonnet, P. Cougot, Georges Houin and Sylvie Saivin. Their work appears in journals such as Journal of Antimicrobial Chemotherapy, Orthopaedics & Traumatology Surgery & Research, Antimicrobial Agents and Chemotherapy, Journal of Clinical Microbiology and Infection.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.